These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 25885592

  • 1. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.
    Gayed BA, Gillen J, Christie A, Peña-Llopis S, Xie XJ, Yan J, Karam JA, Raj G, Sagalowsky AI, Lotan Y, Margulis V, Brugarolas J.
    BMC Urol; 2015 Apr 03; 15():24. PubMed ID: 25885592
    [Abstract] [Full Text] [Related]

  • 2. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW, Petri E, Bichler KH, Feil G.
    Anticancer Res; 1999 Apr 03; 19(4A):2583-90. PubMed ID: 10470199
    [Abstract] [Full Text] [Related]

  • 3. Preoperative high levels of serum vascular endothelial growth factor are a prognostic marker for poor outcome after surgical treatment of renal cell carcinoma.
    Guðbrandsdottir G, Hjelle KM, Frugård J, Bostad L, Aarstad HJ, Beisland C.
    Scand J Urol; 2015 Apr 03; 49(5):388-94. PubMed ID: 25773545
    [Abstract] [Full Text] [Related]

  • 4. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
    Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S, Pode D.
    Urology; 2010 Aug 03; 76(2):513.e1-6. PubMed ID: 20573390
    [Abstract] [Full Text] [Related]

  • 5. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
    Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA.
    Tumour Biol; 2001 Aug 03; 22(5):282-5. PubMed ID: 11553857
    [Abstract] [Full Text] [Related]

  • 6. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma.
    Sato K, Tsuchiya N, Sasaki R, Shimoda N, Satoh S, Ogawa O, Kato T.
    Jpn J Cancer Res; 1999 Aug 03; 90(8):874-9. PubMed ID: 10543260
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma.
    Klatte T, Böhm M, Nelius T, Filleur S, Reiher F, Allhoff EP.
    BJU Int; 2007 Jul 03; 100(1):209-14. PubMed ID: 17428240
    [Abstract] [Full Text] [Related]

  • 8. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
    Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, Pummer K, Zigeuner R.
    Eur Urol; 2007 Jan 03; 51(1):168-73; discussion 174. PubMed ID: 16844285
    [Abstract] [Full Text] [Related]

  • 9. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma.
    Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B.
    J Urol; 2000 Jan 03; 163(1):343-7. PubMed ID: 10604387
    [Abstract] [Full Text] [Related]

  • 10. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
    Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ.
    J Transl Med; 2007 Jul 02; 5():32. PubMed ID: 17605814
    [Abstract] [Full Text] [Related]

  • 11. Serum tissue factor as a biomarker for renal clear cell carcinoma.
    Silva DD, Noronha JAP, Pinheiro da Costa BE, Zandona PCE, Carvalhal GF.
    Int Braz J Urol; 2018 Jul 02; 44(1):38-44. PubMed ID: 28727370
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of plasma and tissue S100A4 protein and mRNA levels as potential markers of metastasis and prognosis in clear cell renal cell carcinoma.
    Yang H, Zhao K, Yu Q, Wang X, Song Y, Li R.
    J Int Med Res; 2012 Jul 02; 40(2):475-85. PubMed ID: 22613408
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor.
    Tanimoto S, Fukumori T, El-Moula G, Shiirevnyamba A, Kinouchi S, Koizumi T, Nakanishi R, Yamamoto Y, Taue R, Yamaguchi K, Nakatsuji H, Kishimoto T, Izaki H, Oka N, Takahashi M, Kanayama HO.
    J Med Invest; 2008 Feb 02; 55(1-2):106-11. PubMed ID: 18319552
    [Abstract] [Full Text] [Related]

  • 14. Increased transforming growth factor beta1 plasma level in patients with renal cell carcinoma: a tumor-specific marker?
    Wunderlich H, Steiner T, Kosmehl H, Junker U, Reinhold D, Reichelt O, Zermann DH, Schubert J.
    Urol Int; 1998 Aug 02; 60(4):205-7. PubMed ID: 9701731
    [Abstract] [Full Text] [Related]

  • 15. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
    Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA.
    Urologe A; 2000 Nov 02; 39(6):554-6. PubMed ID: 11138278
    [Abstract] [Full Text] [Related]

  • 16. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
    Alamdari FI, Rasmuson T, Grankvist K, Ljungberg B.
    Scand J Urol Nephrol; 2007 Nov 02; 41(1):5-9. PubMed ID: 17366095
    [Abstract] [Full Text] [Related]

  • 17. Tissue expression and plasma levels of adrenomedullin in renal cancer patients.
    Michelsen J, Thiesson H, Walter S, Ottosen PD, Skøtt O, Jensen BL.
    Clin Sci (Lond); 2006 Jul 02; 111(1):61-70. PubMed ID: 16515534
    [Abstract] [Full Text] [Related]

  • 18. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics.
    Erdem S, Amasyali AS, Aytac O, Onem K, Issever H, Sanli O.
    Urol Oncol; 2014 Oct 02; 32(7):1031-40. PubMed ID: 25027687
    [Abstract] [Full Text] [Related]

  • 19. [Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor].
    Fujita N, Okegawa T, Tambo M, Shishido T, Nutahara K, Higashihara E.
    Nihon Hinyokika Gakkai Zasshi; 2013 Jan 02; 104(1):1-5. PubMed ID: 23457926
    [Abstract] [Full Text] [Related]

  • 20. Circulating Angiopoietin-2 levels predict mortality in kidney transplant recipients: a 4-year prospective case-cohort study.
    Molnar MZ, Kümpers P, Kielstein JT, Schiffer M, Czira ME, Ujszaszi A, Kovesdy CP, Mucsi I.
    Transpl Int; 2014 Jun 02; 27(6):541-52. PubMed ID: 24628855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.